BioLineRx (NASDAQ:BLRX) Stock Rating Upgraded by Jones Trading

BioLineRx (NASDAQ:BLRX) was upgraded by stock analysts at Jones Trading from a “hold” rating to a “strong-buy” rating in a research report issued on Friday, Marketbeat reports.

A number of other equities research analysts also recently weighed in on BLRX. HC Wainwright reaffirmed a “buy” rating on shares of BioLineRx in a report on Wednesday, May 28th. Wall Street Zen initiated coverage on shares of BioLineRx in a research report on Sunday, May 18th. They issued a “sell” rating for the company.

BioLineRx Stock Performance

Shares of BioLineRx stock traded up $0.61 during trading on Friday, reaching $5.27. The company’s stock had a trading volume of 272,717 shares, compared to its average volume of 219,551. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The business’s fifty day moving average price is $3.23 and its 200-day moving average price is $5.30. The firm has a market cap of $17.54 million, a price-to-earnings ratio of -0.60 and a beta of 1.15. BioLineRx has a one year low of $2.30 and a one year high of $35.60.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, May 27th. The biotechnology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $2.23. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. The business had revenue of $11.75 million for the quarter, compared to analyst estimates of $7.72 million. As a group, equities research analysts predict that BioLineRx will post -5.8 earnings per share for the current year.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC acquired a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent SEC filing. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.